May 11-15, 2026 – Boston, MA
Veristat is pleased to attend the ASGCT Annual Meeting, where leaders across cell and gene therapy come together to share progress, tackle challenges, and shape what comes next. As programs advance through early-phase development, the stakes are high. Scientific complexity, evolving regulatory expectations, and the need for clear, defensible data all converge at this stage.
Our team looks forward to connecting with sponsors and innovators to discuss how Veristat supports cell and gene therapy programs with integrated regulatory, clinical, and biostatistical expertise. The focus is simple: make development capital count and enable faster, more confident decisions as therapies move closer to patients.
Connect with Erin Gaffney, our Senior Business Development Director, to explore how Veristat’s scientific leadership and focused capabilities can help advance your clinical and regulatory milestones.
Complete the form on this page to reserve time with our team. We welcome the opportunity to learn about your upcoming programs and explore how Veristat can support your development strategy.
Whether you're launching a first-in-human study or navigating complex regulatory pathways, Veristat delivers integrated expertise and personalized support across the development lifecycle:
Full-Service Clinical Development Solutions
Clinical Operations Excellence
Let's shape the future of clinical research, together.